Patent ID: 6096763
Filing Date: 2000-08-01
Classification: C07D

Abstract:
A method of treating a condition which is susceptible to treatment by agonism of the mu opioid receptor which comprises administering to a subject in need thereof an amount of a compound effective to treat the condition wherein the compound has the formula: ##STR24## wherein X is selected from N--R.sup.1 or O;R.sup.1 is selected from the group consisting of hydrogen, C.sub.3-6 cycloalkyl, unsubstituted or substituted C.sub.1-6 alkyl where the substituent on the alkyl is selected from mono-, di- or tri-halogen, C.sub.1-4 alkoxy, carboxy, CONH.sub.2, SO.sub.2 NH.sub.2, a heterocyclic ring or aryl, and unsubstituted or substituted C.sub.2-6 alkenyl where the substituent on the alkenyl is selected from mono-, di- or tri-halogen, C.sub.1-4 alkoxy, carboxy, CONH.sub.2, SO.sub.2 NH.sub.2,R.sup.2 is independently one or more of hydrogen, halogen, C.sub.1-4 alkoxy, mono-, di- or tri-halogenated C.sub.1-4 alkoxy or unsubstituted or substituted C.sub.1-6 alkyl where the substituent on the alkyl is selected from mono-, di- or tri-halogen, C.sub.1-4 alkoxy, carboxy, CONH.sub.2, SO.sub.2 NH.sub.2,R.sup.3 is selected from hydrogen, cyano, CO.sub.2 R.sup.1, CONH.sub.2, CONHR.sup.1, CON(R.sup.1 ).sub.2, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl wherein one of the carbon atoms is replaced with a heteroatom selected from O or NH, or unsubstituted or substituted mono- or di-C.sub.1-6 alkyl wherein the substituent on the mono- or di-alkyl is selected from hydroxy, C.sub.1-4 alkoxy, amino or mono-, di- or tri-halogen;R.sup.4 is independently one or more of hydrogen, C.sub.1-6 alkyl, halogen, C.sub.1-4 alkoxy, mono-, di- or tri-halogenated C.sub.1-4 alkoxy, nitro, amino, mono-, di- or tri-halogenated C.sub.1-6 alkyl, C.sub.1-6 alkylsulfonyl, C.sub.1-4 alkylenedioxy, unsubstituted or substituted aryl where the substituent on the aryl is selected from halogen, unsubstituted C.sub.1-3 alkyl, mono-, di- or tri-halogenated C.sub.1-3 alkyl or C.sub.1-4 alkoxy-C.sub.1-3 alkyl, or unsubstituted or substituted heterocyclic ring where the substituent on the heterocyclic ring is selected from halogen, unsubstituted C.sub.1-3 alkyl, mono-, di- or tri-halogenated C.sub.1-3 alkyl or C.sub.1-4 alkoxy-C.sub.1-3 alkyl;R.sup.5 is independently one or more of hydrogen, cyano, C.sub.1-6 alkyl, CO.sub.2 R.sup.1, CONH.sub.2, CONHR.sup.1, CON(R.sup.1).sub.2 ; andn is an integer of from 2 to 4;and the pharmaceutically acceptable salts thereof.